Tele: 561.316.3330
Breaking Medical Device News

Friday, October 15, 2021
HomeSurgical TechnologiesHensler Surgical Technologies Announces Two New Applications for the Hensler Bone Press™...

Hensler Surgical Technologies Announces Two New Applications for the Hensler Bone Press™ – Orthopedic Edition

Hensler Surgical Technologies (HST), in partnership with Ohio native Foot & Ankle Surgeon, Peter Highlander, MD, today announced two new patent-pending Orthopedic applications.  These niche techniques align with HST’s portfolio, strongly driven to local Autograft harvesting for fusion procedures across multiple disciplines.

Since 2012, the Hensler Bone Press™ has been primarily for spinal fusion cases.  The 2 new techniques will initially focus on Intramedullary (IM) post-reaming and tibial condyle harvesting methodology.  The broader range of multi-disciplinary surgical applications, will improve fusion outcomes and cost containment through smaller cortical windows and within the created Tibial medullary canal, already prepared for hardware placement, specifically Tibial IM rods & nails.

“Harvesting cancellous bone and liquid bone marrow, within the tibial condyle(s) and iliac crest is widely accepted1,” said Hensler Surgical Technologies CEO, Sean Hensler.  “We are excited to add these applications for our device beyond the widely successful spinal cases, now exceeding 20,000 cases since launching in 2012.  It was a logical next step, understanding the potential yields of Autograft for these sites.  The device’s 2 new patent-pending techniques adds increased benefit for the patient using local bone and marrow, with little to no new impact to their already planned procedure. I am very proud and humbled the HBP is growing in additional surgical disciplines to help the patient AND the system in these types of cases. The HBP harvests the critical elements necessary for fusion:  Cancellous bone and Bone marrow. ”

Dr. Highlander, an Ohio foot and ankle surgeon stated, “Our goal was to develop new techniques leveraging the capabilities of the bone press that allow for easy, less invasive, and more productive harvesting of lower extremity graft sources. The graft and marrow yield after reaming the tibial canal was more than we anticipated, more so benefiting the patient and containing sheer cost of alternatives.”

The cases performed have proven high yield harvesting of the two critical sources of autologous material.  The device has clinically proven, in 3 & 6 month POST- fusion analysis, indicating radiographically, strong bony union.

The procedures are fully detailed on our website. In Brief,

1. Tibial Condyle Procedure:  We wanted an MIS approach with the smallest cortical window possible.  Additionally, we have seen competitive devices aggressively hollow out the condyles.  Using the high-speed drill and a 4 mm cutting burr, we accomplished precision yields with a cortical window, generally no greater than 6 mm.  This lessens any potential for destabilization and our cases over the last 12 months have proven extremely successful.
2. Intramedullary Post-reaming Procedure:  We postulated after reaming the tibial canal, such as in Charcot’s foot, Cancellous bone and bone marrow was available.  We were surprised by the yields harvested.  On average, nearly 20 cc of Cancellous bone and between 15 – 18 cc of marrow is procured, readily available for fusion.

The Hensler Bone Press™ – Orthopedic Edition is immediately available through Hensler Surgical Technologies.


1 Journal of Foot and Ankle, January-June 2015;2(1): 27-30

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy